---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-039013"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:47:50.365911+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ironwood reiterates FY2025 LINZESS guidance, raises EBITDA to >$105M; Q1 net sales down 46%

## Summary
- Reiterates FY2025 LINZESS U.S. net sales guidance of $800-$850M and total revenue of $260-$290M.
- Raises FY2025 adjusted EBITDA guidance to >$105M (from >$85M).
- Q1 2025 LINZESS U.S. net sales were $138.5M, a 46% decrease YoY due to change in AbbVie's gross-to-net rebate estimate.
- Q1 2025 LINZESS prescription demand grew 8% YoY to 53M capsules, per IQVIA.
- Shifts apraglutide focus to confirmatory Phase 3 trial after FDA feedback; no longer plans certain commercial launch investments.

## SEC filing metadata
- accession: 0001104659-25-039013
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/0001104659-25-039013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/tm2513134d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-039013
- JSON: https://secwatch.observer/filing/0001104659-25-039013.json
- Plain text: https://secwatch.observer/filing/0001104659-25-039013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.